CD30, also known as TNFRSF8, is a cell membrane protein of the tumor necrosis factor receptor family that is widely expressed in Hodgkin’s lymphoma.51 Anti-CD30 antibody drugs have been successfully developed for the treatment of Hodgkin’s lymphoma.52 Currently, seven CAR T trials involving CD30 have been registered in China. This evidence concerns the gene TNFRSF8 and Hodgkins lymphoma.